Orexigen (OREX) - failed diet pill brings FAT profit! Contrave's PDUFA, are you in yet?!

As mentioned in my previous blog entry, Orexigen is booked to hear from the FDA concerning its diet pill's approval on Monday Jan. 31, 2011.  To avoid early announcement by the agency (like what happened with Mannkind), investors are recommended to get in on the trade today or tomorrow (Friday at the latest).  I've devised 3 call/put options combos for readers based on individual's risk tolerance level.  Again, obesity is not directly life threatening and terminal like cancer and has many more options, including diet management and exercise, which are risk-free and proven effective.  As a result, to warrant a green light, any new weight loss drug must demonstrate an outstanding efficacy and safety profile, which Orexigen's Contrave does not possess.

Pick your combo now and see if the failure of this diet pill will leave behind a trail of fat greasy profit.